SGStephen E. Goldstone

Stephen E. Goldstone

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stephen E. Goldstone has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Finally!

    by Stephen E. Goldstone

    Was not provided for this article.

  • Open Access

    Community-Led Operationalization of a Champion Implementation Strategy for Anal Cancer Prevention in Nigeria

    by Megan E. Mansfield, Kareshma Mohanty, John Chama, Connor R. Volpi, Ruxton Adebiyi, Yerima Jibrin Bawa, Kazeem E. Kolawole, Uchenna Ononaku, Oluwole Olaomi, Stephen E. Goldstone, et al.

    Context-specific adaptation of implementation strategies is an important component of promoting evidence-based intervention use. But guidance on systematic approaches is limited. Here we described our mixed method approach to adapting (Study 1) and monitoring (Study 2) a champion implementation strategy to improve implementation of anal cancer prevention procedures at an HIV clinic in Abuja, Nigeria. Building from existing literature, in Study 1, an implementation team of eight Nigerian stakeholders adapted a champion implementation strategy model. Team members ranked different attributes in terms of their importance for defining the strategy. The responses were aggregated and presented to the team who then discussed until consensus was reached on the operationalization of the strategy. In Study 2 we monitored the implementation of the strategy by one champion over six weeks by collecting daily checklists and weekly reflections from the champion. Study 1 team members described the champion as needing to be reliable and confident in using anal cancer prevention procedures, with responsibilities that included providing mentorship and raising awareness. In Study 2 the champion reported engaging in strategy-related activities 75% of the 36-day period (six weeks, each with six days) with coordinating activities (42%) and securing resources (17%) reported most frequently. A thematic analysis revealed four themes depicting the champion’s activities: (1) tool development and procedural changes, (2) capacity building, (3) relationship development, and (4) sustainability efforts. These studies demonstrate an exploratory proof of concept for using community-engaged approaches for adapting implementation strategies to inform both use and monitoring.

  • Open Access

    High Risk of Incident-Persistent Human Papillomavirus Infection With 9-Valent Vaccine Types in Young Men With an HPV Infection

    by Cara J Broshkevitch, Joseph E Tota, Joel M Palefsky, Georges J Nahhas, Stephen E Goldstone, Brady Dubin, Alfred Saah, Alain Luxembourg, Christine Velicer, Anna R Giuliano

    Background: Studies evaluating the association between prevalent human papillomavirus (HPV) infection and the risk of future incident-persistent infection in a broad global sample of men are needed. Methods: Heterosexual men (HM) and men who have sex with men (MSM) aged 16–27 years in the placebo arm of a multinational 4-valent HPV vaccine trial (NCT00090285) were assessed. Incident-persistent infection was defined as a new 9-valent (9v) HPV (HPV6/11/16/18/31/33/45/52/58) type at follow-up that was not present at the same anatomic site at baseline and that remained detectable at that same site for 2 or more consecutive visits approximately 6 months apart. Association between baseline prevalent 9vHPV infection and incident-persistent infection at anogenital sites was estimated using incidence rate differences (IRDs) and incidence rate ratios (IRRs). Results: Included were 1459 HM and 260 MSM. Incidence rates (per 100 person-years) of incident-persistent infection among HM with or without baseline prevalent 9vHPV infection were 10.18 and 5.94, respectively, and among MSM were 11.74 and 9.78, respectively. Baseline prevalent 9vHPV infection status was associated with incident-persistent 9vHPV infection among HM (IRD, 4.24 [95% CI, 1.24–7.23]; adjusted IRR, 1.52 [1.11–2.09]) but not MSM (IRD, 1.96 [−4.01 to 7.93]; adjusted IRR, 1.02 [0.59–1.79]). Conclusions: HM with baseline prevalent 9vHPV infection were more likely to develop an incident-persistent anogenital infection than those without baseline prevalent infection. Risk of incident-persistent infection among MSM was high regardless of baseline prevalent 9vHPV infection status. These findings highlight the importance of vaccinating men against HPV infection.

  • Open Access

    Assessment of Concordant Human Papillomavirus Infection With 9-Valent Vaccine Types Across Anogenital Sites in Young Men

    by Cara J Broshkevitch, Anna R Giuliano, Joel M Palefsky, Georges Nahhas, Stephen E Goldstone, Brady Dubin, Alfred Saah, Alain Luxembourg, Christine Velicer, Joseph E Tota

    Background: The global prevalence of and risk factors associated with same-type HPV infection across multiple anogenital sites among men has not been quantified. Methods: Men aged 16–27 years participating in a multi-country 4-valent HPV vaccine trial (NCT00090285) were assessed at baseline for prevalent HPV infection at penile/scrotal and perineal/perianal sites (heterosexual men [HM] and men who have sex with men [MSM]) and additionally at intra-anal sites (MSM). Concordant infection with 9-valent HPV (9vHPV) vaccine types (6/11/16/18/31/33/45/52/58) was defined as same-type 9vHPV infection at 2 or 3 sites. Results: 3363 HM and 595 MSM were included. Prevalence of concordant 9vHPV infection at 2 anogenital sites was 3.7% among HM and 9.1% among MSM, and 8.2% at 3 sites (including the intra-anal site) among MSM. HPV6 and HPV16 were most likely to occur at multiple anogenital sites in HM and MSM, with strong agreement observed between perineal/perianal and anal sites among MSM for HPV6 (Cohen's kappa, 0.78; 95% CI, .69–.87) and HPV16 (0.61; 95% CI, .50–.73). Conclusions: Concordant anogenital 9vHPV infection was more common among MSM than HM, which is consistent with evidence that MSM are at increased risk of HPV-related cancer across multiple anogenital sites. Clinical Trial Registration: ClinicalTrials.gov, NCT00090285

  • Open Access

    Human papillomavirus (HPV) vaccines in adults: Learnings from long-term follow-up of quadrivalent HPV vaccine clinical trials

    by Stephen E. Goldstone

    The risk for acquiring human papillomavirus (HPV) infections and associated diseases is lifelong. An important part of prophylactic HPV vaccine development is durable protection against infection and disease. With comprehensive long-term follow-up (LTFU) in adolescents, men, and women, the quadrivalent HPV (qHPV) vaccine demonstrated durable effectiveness, immunogenicity, and safety, with almost no breakthrough disease. Those who received a placebo during initial trials were offered the qHPV vaccine at study conclusion and continued to be followed in LTFU extensions. In this catch-up vaccination group, LTFU demonstrated protection even in individuals with current or prior HPV infection after approximately 3 years. The initial efficacy and durable long-term effectiveness of the qHPV vaccine have already translated to a real-world reduction in cancer and cancer precursors. To date, there is no evidence of waning protection; evidence suggests that vaccination ultimately provides strong protection against future disease, with effective prophylaxis even among those with past infections.


  • A Prospective, Dual-Center Trial of Circumferential Radiofrequency Ablation of Anal High-Grade Squamous Intraepithelial Lesions Demonstrate Improved Long-term Efficacy Over Historical Controls of Targeted Ablation

    by Stephen E. Goldstone, Joseph P. Terlizzi, Rebecca A. Levine, Erin M.S. Moshier, Barbara B.S. Pereira Vera

    BACKGROUND: Targeted ablation of anal canal high-grade dysplasia results in high recurrence over time. Circumferential radiofrequency ablation might decrease recurrence. OBJECTIVE: This study aimed to determine the safety and efficacy of circumferential radiofrequency ablation for anal high-grade dysplasia. DESIGN: This was a dual-center, prospective trial of circumferential radiofrequency ablation with a 1-year follow-up with longer follow-up data abstracted from medical records of study patients returning after trial for surveillance. Ten participants from the identically conducted pilot circumferential radiofrequency ablation trial were included to improve sample size for longer-term analysis. SETTINGS: This study included 3 surgeons at 2 sites. PATIENTS: The study included 51 patients undergoing circumferential radiofrequency ablation for anal canal high-grade dysplasia. INTERVENTION: Circumferential radiofrequency ablation of anal canal high-grade dysplasia and targeted radiofrequency ablation of recurrence. MAIN OUTCOME MEASURES: The primary outcome measures were circumferential radiofrequency ablation efficacy and associated morbidity. RESULTS: Fifty-one participants underwent circumferential radiofrequency ablation but 48 participants returned for 1 or more postprocedure high-resolution anoscopy and were evaluable. The mean age of participants was 43 years, most were male (94%), 33% were living with HIV, and 58% had 3 or more high-grade dysplasias treated. Sixty percent had no recurrence, whereas 19% had 1 recurrence, 15% had 2 recurrences, and 6% had 3 recurrences. Most recurrences (66%) developed within the first 6 months. Kaplan-Meier probability of recurrence combining both series was 19% at 3 months, 30% at 6 months, and approximately 40% after 6 months out to 30 months. Most common morbidities were pain (85.4%) lasting for a median of 21 (range, 4–91) days and bleeding (91%) lasting for a median of 21 (range, 5–87) days. Of those with pain and bleeding, 65% and 85%, respectively, described it as mild. No patients developed fistulas, stricture, or incontinence. No serious adverse events related to circumferential radiofrequency ablation occurred. Having a previous recurrence was the only significant predictor of a subsequent recurrence (HR, 28.53) for recurrence at 9 months or before. LIMITATIONS: Enrollment ended prematurely, 10 participants from the pilot study were combined to increase the sample size, and longer-term follow-up was collected retrospectively were the limitations of this study. CONCLUSIONS: Circumferential radiofrequency ablation has improved efficacy over targeted ablation but with increased pain and bleeding. See Video Abstract at http://links.lww.com/DCR/B973. ESTUDIO PROSPECTIVO BICÉNTRICO SOBRE LA ABLACIÓN POR RADIOFRECUENCIA CIRCUNFERENCIAL DE LESIONES ANALES INTRAEPITELIALES ESCAMOSAS DE ALTO GRADO DEMOSTRANDO MAYOR EFICACIA A LARGO PLAZO CON RELACIÓN A CONTROLES HISTÓRICOS DE ABLACIÓN DIRIGIDA: ANTECEDENTES: La ablación dirigida de la displasia de alto grado en el canal anal proporciona como resultados una alta recidiva a largo plazo. La ablación por radiofrecuencia circunferencial podría disminuir la reincidencia. OBJETIVO: Determinar la seguridad y eficacia de la ablación por radiofrecuencia circunferencial para la displasia anal de alto grado. DISEÑO: Estudio prospectivo bicéntrico de ablación por radiofrecuencia circunferencial con un seguimiento de 1 año, en base al monitoreo prolongado de datos, obtenidos de los registros medicos, de todos los pacientes incluidos en el estudio y que fueron controlados clinicamente. Diez participantes del estudio piloto de ablación por radiofrecuencia circunferencial realizada de manera idéntica, se combinaron para mejorar el análisis del tamaño de la muestra a largo plazo. PACIENTES: Se incluyeron 51 pacientes sometidos a la ablación por radiofrecuencia circunferencial de una lesion displásica de alto grado en el canal anal. AJUSTES: Tres cirujanos en 2 centros. INTERVENCIÓN: Ablación por radiofrecuencia circunferencial de la displasia de alto grado en el canal anal y ablación por radiofrecuencia dirigida de la recidiva. PRINCIPALES MEDIDAS DE RESULTADOS: Las medidas primarias fueron la eficacia de la ablación por radiofrecuencia circunferencial y la morbilidad asociada. RESULTADOS: Cincuenta y un participantes se sometieron a la ablación por radiofrecuencia circunferencial, de los cuales, 48 regresaron para ser evaluados con ≥1 anuscopias de alta resolución, después del procedimiento. La edad media de los participantes fue de 43 años, en su mayoría hombres (94%), el 33% eran portadores de VIH y el 58% tenía ≥3 lesiones displásicas de alto grado tratadas. El sesenta por ciento no tuvo recidiva, mientras que el 19%, 15% y 6% tuvieron 1, 2 o 3 recidivas. La mayoría de las recaídas (66%) se desarrollaron dentro de los primeros 6 meses. La probabilidad de recurrencia de Kaplan-Meier combinando ambas series fue del 19 % a los 3 meses, del 30 % a los 6 meses y aproximadamente del 40 % entre los 6 y 30 meses. Los indicadores de morbilidad más frecuentes fueron, el dolor (85,4%) con una mediana de duración de 21 días (rango, 4-91) y sangrado (91%) con una mediana de duración de 21días (rango, 5-87). Aquellos pacientes con dolor (65%) y sangrado (85%) respectivamente, los describieron como leves. Ningún paciente desarrolló fístula, estenosis o incontinencia. No se produjeron eventos adversos graves relacionados con la ablación por radiofrecuencia circunferencial. Tener una recurrencia previa fue el único factor predictivo importante de una recidiva ulterior (RH 28,53) en casos de recaída a los 9 meses o antes. LIMITACIONES: Como el registro finalizó prematuramente, se agregaron 10 participantes del estudio piloto para aumentar el tamaño de la muestra. El seguimiento a largo plazo fué recopilado retrospectivamente. CONCLUSIONES: La ablación por radiofrecuencia circunferencial ha mejorado la eficacia sobre la ablación dirigida pero con dolor y sangrado mas importantes. Consulte Video Resumen en http://links.lww.com/DCR/B973. (Traducción—Dr. Xavier Delgadillo)


  • Efficacy, immunogenicity, and safety of a quadrivalent HPV vaccine in men: results of an open-label, long-term extension of a randomised, placebo-controlled, phase 3 trial

    by Stephen E Goldstone, Anna R Giuliano, Joel M Palefsky, Eduardo Lazcano-Ponce, Mary E Penny, Robinson E Cabello, Edson D Moreira, Ezio Baraldi, Heiko Jessen, Alex Ferenczy, et al.


  • ANCHOR Trial Results Are In: So Where Do We Go From Here?

    by Goldstone, Stephen E.

    An abstract is unavailable. This article is available as a PDF only.